Immunocore Holdings plc Operating Lease, Weighted Average Discount Rate, Percent
Immunocore Holdings plc (IMCR) had Operating Lease, Weighted Average Discount Rate, Percent of 7.30% as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-02-25
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.30%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.40%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.20%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.20%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 7.30% 10-K · filed 2026-02-25 |
| 2024-12-31 | 7.40% 10-K · filed 2026-02-25 |
| 2023-12-31 | 7.20% 10-K · filed 2025-02-26 |
| 2022-12-31 | 7.20% 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |